TNF-alpha (Infliximab biosimilar) Antibody from ABBEXA LTD
Search, find, compare suppliers for anti-TNF-alpha (Infliximab biosimilar) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | TNF-alpha (Infliximab biosimilar) |
| Clone | monoclonal |
| Host Species | Chimeric Human/Mouse |
| Reactive Species | human |
| Isotype | IgG1 kappa |
| Format | Protein A/G purified |
| Size | 100 µg, 1 mg, |
| Concentration | typically between 0.5-2.0 mg/ml. |
| Applications | ELISA, WB |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Infliximab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNF-alpha, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Infliximab is a humanized antibody against tumor necrosis factor ? (TNF-?) that is used in the treatment of Crohn's disease and rheumatoid arthritis. Infliximab is a IgG1? monoclonal antibody that binds to soluble and transmembrane forms of TNF-? with high affinity to disrupt the pro-inflammatory cascade signalling. Binding of the antibody to TNF-? prevents TNF-? from interacting with its receptors. Infliximab does not neutralize TNF-? (lymphotoxin-?), a related cytokine that utilizes the same receptors as TNF-? Label. Blocked actions of TNF-? further leads to downregulation of local and systemic pro-inflammatory cytokines (i. e. IL-1, IL-6), reduction of lymphocyte and leukocyte migration to sites of inflammation, induction of apoptosis of TNF-producing cells (i. e. activated monocytes and T lymphocytes), increased levels of nuclear factor-?B inhibitor, and reduction of reduction of endothelial adhesion molecules and acute phase proteins 3. Its inhibitory actions on TNF-? was demonstrated in human fibroblasts, endothelial cells, neutrophils, B and Tlymphocytes and epithelial cells Label. Infliximab also atteunates the production of tissue degrading enzymes synthesized by synoviocytes and/or chondrocytes. According to a transgenic mice study that developed polyarthritis due to consitutive levels of human TNF-?, infliximab decreased synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal Label. |
| Immunogen | n/a |
| Other Names | Infliximab, TNF-alpha, 170277-31-3 |
| Gene, Accession # | CAS: 170277-31-3 |
| Catalog # | abx831069 |
| Price | please inquire |
| Order / More Info | TNF-alpha (Infliximab biosimilar) Antibody from ABBEXA LTD |
| Product Specific References | n/a |
ABBEXA LTD
ABBEXA LTD
181 Cambridge Science Park
Cambridge, CB4 0GJ UK
P: +44 (0) 1223 755950
Customer Service: info@abbexa.com
Technical Support: support@abbexa.com
Orders: orders@abbexa.com
https://www.abbexa.com
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950
Profile of ABBEXA LTD
Return to Antibodies